Carcinoma In Situ Breast cancer


ASCO Publishes Breast Cancer Survivorship Guidelines (01-25-2016)

The American Society of Clinical Oncology (ASCO), in collaboration with the American Cancer Society (ACS), have released updated guidelines regarding follow-up care for breast cancer survivors. The updated guidelines were recently published in the Journal... Continue Reading

Quality of Life Helps Determine Type of Hormone Treatment in Early Breast Cancer (01-20-2016)

Quality of life issues and different side effects caused by treatment may help determine which type of hormone therapy is most appropriate for postmenopausal women with ductal carcinoma in situ, particularly among women 60 years of age or older. These... Continue Reading

Radiation Essential to Controlling Long-Term Recurrence in Women With Early Form of Breast Cancer (10-1-2015)

Doctors have reported that rates of breast cancer recurrences continue to increase, even after 12 years, among patients with ductal carcinoma in situ (DCIS) who do not receive radiation therapy as part of their treatment regimen. These results were recently... Continue Reading

Biomarker May Help Improve Treatment of Triple-Negative Breast Cancer (09-8-2015)

Researchers have found a biomarker that appears active in the growth and spread of triple-negative breast cancer. Known as interleukin-13 receptor alpha 2 (IL13Ralpha2), the biomarker may help doctors identify patients at high risk of disease spread and... Continue Reading

Women with Early Breast Cancer Have Fewer Side Effects with Shorter Courses of Radiation (09-1-2015)

Women with early breast cancer have fewer side effects when they’re treated with shorter courses of radiation at higher doses than with conventional radiation to the whole breast. These findings were reported in JAMA Oncology.[1] Treatment with shorter... Continue Reading

Breast Cancer Research and Treatment Publishes Oncotype DX(R) DCIS Score(TM) Study Conducted in Canada (08-27-2015)

Genomic Health, Inc. (Nasdaq: GHDX) announced that Breast Cancer Research and Treatment published results from a second large clinical validation study of Oncotype DX® in patients with stage 0 breast cancer, also known as DCIS (Ductal Carcinoma In Situ).... Continue Reading

Arimidex® More Effective than Tamoxifen in Prevention of Recurrence in Early Breast Cancer (06-9-2015)

For patients with a common type of breast cancer known as ductal carcinoma in situ (DCIS), the drug Arimidex® (anastrozole) may provide better protection against recurrence than tamoxifen. These findings were presented at 2015 Annual Meeting of the American... Continue Reading

Breast Cancer Research: Have We Made Progress? (01-27-2015)

Published results from research studies in breast cancer in the last year represent several practice changing milestones. CancerConnect News coverage of advances in the management of breast cancer included the following key developments: 2014: Have we... Continue Reading

Ask the Expert: Making Informed Decisions about Early-Stage Breast Cancer Treatment (10-15-2014)

October 23, 2014 at 6:00pm EDT CancerConnect live Web Chat with an Expert sereis presents: “Rethink Pink: From Awareness to Knowledge, Advice for women newly diagnosed with early stage breast cancer.” On October 23, 2014 at 6:00pm EDT you will have... Continue Reading

Walk or Run Your Way to a Reduced Risk of Breast Cancer (09-24-2014)

Want to reduce your risk of breast cancer? Lace up those shoes and get moving—because exercise has a significant impact. There is a growing body of evidence to indicate that exercise is crucial to reducing the risk of cancer. Now a new study has put... Continue Reading

Next Page »